ArticleBiometrical journal. Biometrische Zeitschrift2019

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.

Jose L Jimenez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.